key: cord-0285664-ciwozpc0 authors: Barreiro, Antonio; Prenafeta, Antoni; Bech-Sabat, Gregori; Roca, Mercè; Perozo, Eva; March, Ricard; González, Luis; Madrenas, Laia; Corominas, Júlia; Fernández, Àlex; Molas, Mercè; Pentinat, Thais; Panosa, Clara; Moreno, Alberto; Puigvert, Ester; Pol, Eva; Palmada, Jordi; Garriga, Carme; Prat, Teresa; Vergara-Alert, Júlia; Lorca-Oró, Cristina; Roca, Núria; Fernández-Bastit, Leira; Rodon, Jordi; Pérez, Mònica; Segalés, Joaquim; Pradenas, Edwards; Marfil, Silvia; Trinité, Benjamin; Ortiz, Raquel; Clotet, Bonaventura; Blanco, Julià; Pedroza, Jorge Díaz; Carrasco, Rosa Ampudia; Salgado, Yaiza Rosales; Loubat-Casanovas, Jordina; Larripa, Sara Capdevila; Prado, Julia Garcia; Barretina, Jordi; Sisteré-Oró, Marta; Rica, Paula Cebollada; Meyerhans, Andreas; Ferrer, Laura title: Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate based on a novel recombinant RBD fusion heterodimer of SARS-CoV-2 date: 2021-11-29 journal: bioRxiv DOI: 10.1101/2021.11.22.469117 sha: 97de3767ddba1d49a93804f964dfcf03533269cf doc_id: 285664 cord_uid: ciwozpc0 Since the genetic sequence of SARS-CoV-2 became available in January 2020, new vaccines have been developed at an unprecedented speed. The current vaccines have been directly associated with a decline in new infection rates, prevention of severe disease and an outstanding decrease in mortality rates. However, the pandemic is still far from being over. New Variants of Concern (VoCs) are continuously evolving. Thus, it is essential to develop accessible second-generation COVID-19 vaccines against known and future VoCs to mitigate the current pandemic. Here, we provide preclinical data showing the immunogenicity, efficacy, and safety results in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine candidate (PHH-1V) which consists of a novel RBD fusion heterodimer containing the B.1.1.7 (alpha) and B.1.351 (beta) variants of SARS-CoV-2, formulated with an oil-based adjuvant equivalent to MF59C.1. BALB/c and K18-hACE2 mice were immunized with different doses of recombinant RBD fusion heterodimer, following a two-dose prime-and-boost schedule. Upon 20 μg RBD fusion heterodimer/dose immunization, BALB/c mice produced RBD-binding antibodies with neutralising activity against the alpha, beta, gamma, and delta variants. Furthermore, vaccination elicited robust activation of CD4+ and CD8+ T cells with early expression of Th1 cytokines upon in vitro restimulation, along with a good tolerability profile. Importantly, vaccination with 10 μg or 20 μg RBD fusion heterodimer/dose conferred 100% efficacy preventing mortality and bodyweight loss upon SARS-CoV-2 challenge in K18-hACE2 mice. These findings demonstrate the feasibility of this novel recombinant vaccine strategy, allowing the inclusion of up to 2 different RBD proteins in the same vaccine. Most importantly, this new platform is easy to adapt to future VoCs and has a good stability profile, thus ensuring its global distribution. In December 2019, the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was identified as the etiological agent of the novel Coronavirus disease 2019 . Soon after that, the scientific community and the pharmaceutical industry began focusing on the development of effective COVID-19 vaccines to mitigate the health emergency. Thanks to these efforts, several vaccines are currently available, and more than 7 billion doses have been administered worldwide (November 2021) (WHO, 2021) . The decline in new infection rates in many countries coincides with the introduction of vaccines. However, COVID-19 cases continue to emerge, probably due to the appearance and evolution of novel SARS-CoV-2 variants, the decline of immunological protection provided by the current vaccines, and, especially, the lack of homogenous distribution of COVID-19 vaccines, with only 4.4% of people in low-income countries having received at least one dose (November 2021) (Hannah Ritchie et al., 2020; Mathieu et al., 2021) . As the global outbreak continues, the pandemic is far from being over, and it is not clear if the available vaccines will be sufficient to revert the situation. Thus, it is still critical to develop second-generation vaccines using different platforms that are effective against novel variants and that could be further used as a booster, particularly to maintain or even enhance immunity against SARS-CoV-2 (Günl et al., 2021; Moyo-Gwete et al., 2021) . Moreover, it is of relevance that these novel vaccines can be stored in refrigerated conditions, making them easier to distribute, avoiding lower and less available extremely low storage temperature conditions to ensure their global supply. Currently, authorised vaccines, either approved under emergency use or with full license, and vaccine candidates are based on viral vectored approaches, inactivated viruses, nucleic acid-based vaccines, and subunit vaccines. The SARS-CoV-2 is a novel betacoronavirus, which belongs to the subfamily Coronovirinae within the family Coronaviridae and the order Nidovirales. The SARS-CoV-2 genome is a single-stranded positive-sense RNA (+ssRNA) molecule. The genome size ranges between 27 and 32 kbp, one of the largest known RNA viruses. The genomic structure of SARS-CoV-2 contains at least six Open Reading Frames (ORFs), encoding for at least four structural proteins, namely: envelope or spike (S) glycoprotein S; membrane (M) proteins, responsible for the shaping of the virions; envelope (E) proteins, responsible for the virions assembly and release; and nucleocapsid (N) proteins, involved in the RNA genome packaging (Alanagreh, Alzoughool and Atoum, 2020). The trimeric S glycoprotein of SARS-CoV-2 is the primary target of viral neutralising antibodies and has been the main protein candidate for vaccine development (Vogel et al., 2020) . Consistent with SARS-CoV, angiotensin-converting enzyme 2 (ACE2) binding of the S protein allows cellular entry of SARS-CoV-2 viral particles (Zhou et al., 2020) . This protein consists of 2 domains, S1 and S2, allowing the binding of the viral particles and the cellular entry by fusing with the host cell membrane (Huang et al., 2020) . The receptor binding domain (RBD) (Thr333-Gly526) is found in the S1 domain, and it contains a highly immunogenic receptor binding motif (RBM) that directly interacts with ACE2 and neutralising antibodies (Yi et al., 2020) . Therefore, the majority of key mutations are found in the RBM, allowing the virus adapting to the previous developed immunity. To date, several SARS-CoV-2 VoCs with key mutations in the S protein have emerged: alpha (B.1.1.7), beta (B.1.351), gamma (P.1) and delta (B.1.617.2) (Plante et al., 2021) . The S protein is the primary target in vaccine development against betacoronaviruses due to its accessibility for immune recognition (Dai and Gao, 2021) . It has been reported that two proline substitutions in the original S protein sequence (S-2P) of MERS-CoV, SARS-CoV and HKU1 coronavirus maintain the antigenic conformation (Pallesen et al., 2017) . Thus, learning from these previous results, this S-2P design is used in the authorised mRNA-based vaccines Comirnaty® (Pfizer-BioNTech) (Comirnaty SmPC, 2021) and Spikevax® (Moderna) (Spikevax SmPC, 2021) , which substitute the residues K986 and V987 for prolines from the original S protein variant. Likewise, the adenoviral vector-based vaccine Janssen (Johnson & Johnson) also contains DNA-encoding for the S-2P protein of the SARS-CoV-2 (COVID-19 Vaccine Janssen, 2021). Adjuvanted protein-based subunit vaccines represent an important type of vaccines, yet their development has lagged compared to other platforms due to the need to optimise the manufacturing process for each protein antigen. The most advanced subunit vaccine programme against COVID-19 is the Novavax vaccine candidate, (NVX-CoV-2373) , which is produced in insect cells in combination with a saponin-based adjuvant (Matrix-M) (Keech et al., 2020) . This vaccine candidate consists of the stable full-length S protein in the antigenically optimal prefusion conformation. In addition, the Sanofi-GSK vaccine candidate consists of soluble prefusion-stabilized S trimers from SARS-CoV-2 produced in insect cells with the AS03 adjuvant (Francica et al., 2021) . Both vaccine candidates are currently being tested in human clinical trials (Keech et al., 2020b; Goepfert et al., 2021) . Notably, recombinant proteins are competitive vaccine candidates with an adequate safety profile, no risk of genome integration, no live components, and suitable for people with compromised immune systems (Kyriakidis et al., 2021) , showing high productivity yields and good stability profiles (Gavi Alliance-Covax collaboration platform, 2021; Kleanthous et al., 2021; Kyriakidis et al., 2021) . The majority of cloned neutralising antibodies target the RBD in the S1 domain (Piccoli et al., 2020) , although there are additional immunogenic epitopes outside this domain (Wang .et al, 2020) . Considering that the RBD domain of the S protein directly interacts with the ACE2 receptor, and therefore, RBD-targeting antibodies are not expected to cause Antibody-Dependent Enhancement (ADE), unlike non-neutralising or sub-neutralising antibodies (Lee et al., 2020) , these data highlight the importance of RBD in the immune response against SARS-CoV-2. Given the inherent particularities of the S protein, and especially the RBD domain, our team developed a vaccine-candidate platform based on this immunogen. Among the tested preliminary vaccine-candidates, combined with one or several adjuvants, we finally proceeded with a protein-based subunit vaccine candidate, namely PHH-1V, consisting of a recombinant RBD fusion heterodimer of the B.1.1.7 and B.1.351 variants of SARS-CoV-2 produced in Chinese Hamster Ovary (CHO) cells with an oil-based adjuvant equivalent to MF59C.1. Specifically, MF59C.1 is an oil-in-water emulsion adjuvant that stimulates the immune response, the safety of which is well-known in humans since approximately 100 million doses have been already distributed to populations including pregnant women and children (Ko and Kang, 2018) . Thus, the main aims of this study were to assess the safety and efficacy of the PHH-1V vaccine in BALB/c and K18-hACE2-transgenic mice models, and to characterise the RBD fusion heterodimer antigen and its immunogenicity. The antigen of the PHH-1V vaccine candidate is the SARS-CoV-2 virus recombinant S protein RBD fusion heterodimer consisting of the B.1.351 and B.1.1.7 variants. This recombinant subunit antigen is a RBD fusion heterodimer antigen formed by two monomers (Figure 1(A) ). The Nterminal monomer contains the amino acid sequence of the SARS-CoV-2 RBD protein from the B.1.351 (beta) variant, whereas the C-terminal monomer contains the homologous sequence from the B.1.1.7 (alpha) variant. According to the structural modelling, the critical mutations involved in the higher affinity towards the human ACE2-receptor and the potential immune escape of both variants are clearly exposed on the protein surface. The heterodimer is expressed in mammalian CHO cells and is used with an oil-in-water adjuvant equivalent to MF59C.1. After expressing the antigen in a bioreactor fed-batch cultivation, it is purified by a complex downstream process consisting of sequential stages, including depth and tangential filtration, chromatography steps, and sterile filtrations. The final product is a highly purified antigen, as determined by SDS-PAGE and SEC-HPLC (Figure 1 (B, C) , suitable for vaccine formulation. Surface plasmon resonance (SPR) analysis showed an affinity constant for hACE2 of 0.099 nM (Figure 1 (D) ). The mouse strain B6.Cg-Tg(K18-ACE2)2Prlmn/J (K18-hACE2) (Jackson Laboratories, ME, USA) and BALB/c (Envigo, IN, USA) were immunized with different doses of the recombinant RBD fusion heterodimer antigen. The prime immunization with the PHH-1V candidate induced higher titres of RBD binding antibodies in the groups C to F compared to the control (group A) on day 21 post-first immunization (D21) (p<0.05) (Figure 2(A) ). After the prime-boost immunization, all vaccinated groups (B to F) reached higher IgG titres than the control group on D35/D37 (14/16 after the boost; p<0.01). At D35/D37, specific SARS-CoV-2 RBD-binding antibodies were detected in groups B to D in a dose-dependent manner, with significant differences among these groups (p<0.01). However, no significant differences were observed among the groups immunized with more than 1 µg of recombinant RBD fusion heterodimer antigen (groups D to F). Thus, the IgG response was saturated from 1 µg immunization. Likewise, the RBD-specific binding antibody titres were also increased in SARS-CoV-2 infected K18-hACE2 mice upon vaccination (group C and D) compared to infected and non-infected PBS-vaccinated mice (group A and B) ( Figure S1 ). Both vaccinated groups had similar RBD-specific antibody titres and were vaccinated with 10 or 20 µg of recombinant protein RBD fusion heterodimer, respectively. To estimate the type of cellular immune response elicited by the vaccine, the IgG2a/IgG1 ratios were calculated as a surrogate of the Th1/Th2 cellular immune response. The IgG2a/IgG1 ratio of groups E and F was 0.74 and 0.75, respectively, which suggests a balanced Th1/Th2 immunogenic response upon PHH-1V vaccination in mice (Figure 2(B) ). SARS-CoV-2 neutralising antibodies titres in sera from BALB/c mice were determined by Pseudovirus-based neutralisation assay (PBNA) against the S protein of different variants on D35/D37 (14/16 days after the boost). Prime-boost immunization of groups C to F induced higher neutralising antibody titres against the S protein of the alpha variant compared to the control group A (p<0.01) (Figure 3(A) ). No neutralising antibody response was observed in group B, although IgG binding antibodies were detected on D35/D37. The mean neutralising antibody titres observed in groups C to E remained the same since no statistically significant differences were observed. However, vaccination with 20 µg of RBD fusion heterodimer antigen (group F) induced higher neutralising titres than groups C and D. In fact, high neutralising titres against all the tested variants (alpha, beta, gamma, and delta) were detected in sera from group F (Figure 3 (B)), especially for the alpha and beta variants. On the other hand, the SARS-CoV-2 neutralising antibodies against the original variant (Wuhan) were increased in SARS-CoV-2 infected humanized K18-hACE2 mice upon vaccination (groups C and D) compared to infected and noninfected PBS-vaccinated mice (groups A and B) ( Figure S2) . Notably, the levels of neutralising antibodies were similar between both vaccinated groups. The characterization of the antigen-specific response of splenic T cells 14-16 days after the boost immunization was performed by intracellular cytokine staining (ICS) and enzyme-linked immunospot (ELISpot) assays in female BALB/c mice from groups A (control), E and F (vaccinated with 5 µg or 20 µg of recombinant protein RBD fusion heterodimer, respectively). The ICS data indicate that upon the stimulation with an RBD peptide pool, splenocytes from group F displayed significant activation of CD4 + T cells expressing IFN-γ (p<0.01) and IL-2 (p<0.05) compared to the control group (Figure 4 (A) ). No significant antigen-specific response of CD4 + T cells expressing TNF-α or IL-4 was observed in group F when compared to the control group. Notably, immunization of mice with a lower RBD dose (group E) did not induce IFN-ɣ, TNF-α, IL-2 or IL-4 producers' memory CD4 + T cells after the in vitro restimulation. Furthermore, splenocytes from group F showed significant activation of CD8 + T cells expressing IFN-γ (p<0.05) and IL-2 (p<0.01) after the antigen-specific restimulation (>0.1% activation) compared to the control group (Figure 4(B) ). No CD8 + T cell response was observed in splenocytes from group E compared to the control group. Hence, considering the T cells expressing any of the analysed Th1 cytokines (IFN-γ, TNF-α and IL-2), group F showed a higher CD4 + T cell response than the control group (p<0.05), and a higher percentage of animals showed activated CD8 + T cells (p<0.05) (>0.25% activation) ( Figure S3 ). The IFN-ɣ and IL-4 ELISpot assays showed no significant differences between the two doses of recombinant protein RBD fusion heterodimer (group E vs group F) ( Figure 5 ). However, both groups showed a higher percentage of IFN-ɣ + and IL-4 + spots compared to the control group (p<0.01). Importantly, the percentage of IFN-ɣ + and IL-4 + in group F was similar, denoting a balanced Th1/Th2 response, while the percentage of IL-4 + spots was significantly higher than IFN-ɣ + spots in group E (p<0.01), suggesting a Th2-biased response in mice immunised with 5 µg of recombinant protein RBD fusion heterodimer. The extracellular cytokine levels were measured by Luminex Multiplex in supernatants from splenocytes stimulated with a pool of peptides from SARS-CoV-2 RBD. The levels of IL-2 (p<0.05), IL-5 (p<0.01) and TNF-α (p<0.05) were higher in the supernatants from group E splenocytes compared to the control group (Figure 6) . Similarly, the levels of IL-5 (p<0.01) and TNF-α (p<0.05) were statistically higher in group F compared to group A. A tendency towards an increase in the levels of IL-2 (p=0.062) was also observed in group F compared to group A. To analyse the protective efficacy of the vaccine candidate PHH-1V against COVID-19 and the pathogenic outcomes derived from the SARS-CoV-2 infection, K18-hACE2 mice were used as a challenge model. All groups were vaccinated intramuscularly following the two-dose prime-andboost schedule: 1 st dose (prime) at D0 and 2 nd dose (boost) at D21. The SARS-CoV-2 challenge was performed on a subset of animals at D35 through intranasal infection. The primary endpoint reporting the protective capacity of the vaccine candidates was weight loss and/or mortality post-challenge. Survival curves are presented in Figure 7 (A). Clinical signs of the SARS-CoV-2 infection were observed only in the non-vaccinated and infected group (B) on days 5 (3 animals) and 6 (3 animals) post-challenge. In all cases, clinical signs led to end-point criteria and the animals were euthanised. Thus, survival curves were significantly different among the different groups (p<0.001). The weekly individual body weights of each group during the vaccination period and post-challenge are shown in Figures S4 (B) and 7 (B), respectively. Animals of group B experienced a remarkable weight loss from D3 post-challenge onwards, as expected due to the COVID-19 infection, showing a significantly lower weight compared with vaccinated animals from group D on D5 post-challenge (p<0.05) and from groups C and D on D6 post-challenge (p<0.01). Total viral RNA was determined in oropharyngeal samples (Figure 8 (A) ), lungs, nasal turbinate, brain (Figure 8 (B) ), trachea, pharynx, spleen and heart (Figure 8 (C) ). Viral RNA was determined by quantitative real-time quantitative polymerase chain reaction (RT-qPCR) at D37 (2 days postinfection), D39 (4 days post-infection), D42 (in males, 7 days post-infection) and D43 (in females, 8 days post-infection), or at the time of euthanasia in animals reaching end-point criteria before the scheduled euthanasia day. As it can be seen in Figure 8 (A, B, C), immunization with both doses of PHH-1V (10 μg or 20 μg of recombinant protein RBD fusion heterodimer), reduced the viral load measured by PCR in oropharyngeal swabs, lungs, nasal turbinate, brain, trachea, pharynx, spleen and heart after the experimental infection compared to the infected control (group B). Virus titres were determined using a standard 50% tissue culture infectious dose (TCID50) assay on positive samples of qPCR. No infectious virus was detected in oropharyngeal swabs, pharynx, spleen and trachea. Regarding heart samples, only one out of the three positive samples by RT-qPCR resulted positive in viral isolation in cell culture (group B at D4). For the other organs, the results are shown in Figure 9 . For the analysed tissues, the samples from group D had a significant lower infective viral load at D2 post-challenge and a tendency towards a decrease compared to group B at D7. Likewise, the group C showed a tendency towards a decrease in the infective viral load compared to group B at D2 post-challenge. Histopathological analyses were determined in the nasal turbinate, lungs, and brain for all animals. In other non-main target tissues of the virus (spleen, trachea, or heart), 2 animals per group were analysed. No lesions were found in the spleen, trachea, and heart of any of the studied animals. As it can be seen in Figure 10 , considering data from all days, the infected nonvaccinated control (group B) had a higher histopathological score in the lungs compared to group C (p<0.05) and in the brain compared to group C (p<0.005) and D (p<0.005). No significant differences between groups were observed in the histopathological score of the nasal turbinates. The preclinical safety of the PHH-1V candidate vaccine was evaluated on BALB/c mice immunised with different doses of the RBD fusion heterodimer, by measuring the bodyweight of each animal once a week until D35/D37. For additional safety information, clinical signs and local reactions were monitored. No differences in the bodyweight were observed between the different dose groups (Figure S4 (A)), and no clinical signs or local reactions were detected after the vaccinations in BALB/c mice. Additionally, the PHH-1V safety was evaluated in humanised K18-hACE2 mice and bodyweight and clinical signs were also monitored during the vaccination period. As observed with the BALB/c mice, no significant changes in the bodyweight were observed between the different groups ( Figure S4 (B)) and vaccinated animals did not show clinical signs or local reactions. The histological evaluation in the injection site revealed a mild lesion, with multifocal mononuclear inflammatory infiltrates within and around muscular fibres, in one of the hind limbs of 1 animal vaccinated with 10 μg RBD fusion heterodimer/dose at D2 and 2 animals vaccinates with 20 μg RBD fusion heterodimer/dose at D4 post-challenge (Figure 10 ). In this study, the effect of the recombinant protein RBD fusion heterodimer dose on the immunogenicity and safety of the PHH-1V vaccine was tested in BALB/c and K18-hACE2 mice. Furthermore, the preclinical efficacy of the vaccine candidate was also assessed in SARS-CoV-2infected and non-infected K18-hACE2 mice. We show that the active substance of the PHH-1V vaccine candidate, the RBD fusion heterodimer, is stable and has an affinity constant of 0.099 nM against the human ACE2 receptor, which indicates an outstanding binding affinity with its natural ligand. The whole sequence of the antigen originates from the SARS-CoV-2 RBD domains of the B.1.1.7 (alpha) and B.1.351 (beta) variants, which have been shown by Ramanathan et al. (2021) to bind ACE2 with increased affinity. We were able to obtain the antigen at high purity, which is consistent with its use as an active drug substance in a vaccine. CHO, the expression system selected to produce this antigen, has been a workhorse for decades for the production of monoclonal antibodies and other protein-based therapeutic entities (Sharker and Rahman, 2021) . It has been clearly accepted by regulatory agencies worldwide for this purpose. The PHH-1V vaccine candidate was shown to be safe in mice since the tested doses did not cause clinical signs (general and local) nor bodyweight loss in either immunised BALB/c or K18-hACE2 mice. Although the histological evaluation of the injection sites revealed mild lesions with cellular infiltrates in few vaccinated animals, these were attributable to the local innate immune response induced upon injection with adjuvant-containing vaccines (Singh M, O'Hagan, 1999) We consistently observed an adequate safety profile in other animal species in which the PHH-1V vaccine candidate has been tested, such as rats, rabbits, cynomolgus monkeys and pigs (unpublished data). The oil-based adjuvant equivalent to MF59C.1 used in this vaccine might be related to the good tolerability shown in animal models, as it is based on an adjuvant that is widely regarded as safe in humans (O'Hagan et al., 2013) . Regarding the RBD-binding antibodies humoral response, a dose-response was observed at D35/D37 upon vaccination with RBD heterodimer doses of 0.04, 0.2 and 1 μg/dose, however, this response saturates with higher immunization doses. Significant total IgG titres were observed even after one dose for doses of 0.2 μg and above. These results suggest a good potency profile for antigen included in the PHH-1V vaccine candidate, with similar or superior performance to other previously reported immunogens based on similar platforms (Figure 2 (A)) (Kuo et al., 2020; Tian et al., 2021) . Moreover, potent pseudovirus-neutralising activity against the alpha variant was elicited by 0.2 μg RBD fusion heterodimer/dose immunization, reaching the highest titres with the 20 µg RBD fusion heterodimer/dose immunization. Furthermore, a robust pseudovirus-neutralising activity of sera from mice immunised with 20 µg of RBD fusion heterodimer/dose was confirmed against the beta, gamma, and delta variants. This crossreactivity was previously confirmed in earlier exploratory trials, where no significant differences were observed in the pseudovirus-neutralising titres against the alpha, beta, and gamma variants in mice upon vaccination with 20 μg RBD fusion heterodimer/dose (data not shown). Notably, the pseudovirus neutralization assays from this work were performed in the same laboratory and under the exact same conditions as those that were previously reported to have a good correlation with live virus neutralization assays (Trinité et al., 2021) , which highlights the biological relevance of the obtained neutralising antibody titres that were obtained. Previous results show that upon vaccination with mRNA-based vaccines (Spikevax® and Comirnaty®), the SARS-CoV-2 neutralization capacity is significantly decreased against the gamma and beta variants, even in fully vaccinated individuals. This reduction in neutralization capacity is similar to the delta variant (García-Beltran et al., 2021; Planas et al., 2021; Wall et al., 2021) . Thus, even though the recombinant protein RBD fusion heterodimer was designed to elicit a response against the SARS-CoV-2 alpha and beta variants, our data also demonstrate a further neutralising activity against the novel delta variant, which is currently dominant around the world to date (Hadfield et al., 2018 ; Genomic epidemiology of novel coronavirus -Global subsampling., 2021). This is critical to mitigating the current pandemic situation, although further studies will have to confirm our findings in human subjects. Moreover, our antigen contains several mutations that are of high concern, mutations which are present in currently designated VoCs and which could potentially arise in future variants. That includes the E484K substitution present in beta and the more recently emerged B.1.621 (mu) variant. E484K is related to immune escape and reduced antibody neutralization, compromising the efficacy of currently approved vaccines (Jangra et al., 2021) . In regard to the cellular response upon vaccination, the ICS data indicate that immunization with the highest dose of 20 μg RBD fusion heterodimer/dose induced a robust Th1-dominant response with activation of CD4 + and CD8 + T cells expressing IFN-γ and IL-2. Notably, no significant IL-4 expression was detected by ICS in the splenocytes from immunised animals. However, the expression of this Th2 cytokine was detected by IL-4 ELISpot assays in splenocytes from both immunised groups. Specifically, according to the ELISpot results, the immunization with 5 μg RBD fusion heterodimer/dose elicited a Th2-biased response, while the immunization with 20 μg RBD fusion heterodimer promoted a balanced Th1/Th2 response. These differences in the cytokine expression between both assays might be explained by the differences in the incubation time of the splenocytes after the RBD peptide pool stimulation, which was 48h for the ELIspot compared to 5h for the ICS. Furthermore, the experimental conditions (number of splenocytes and incubation time) assayed to detect IFN-ɣ and IL-4 via ELISpot were different; hence, these data have to be interpreted carefully. It is known that, for most infections, Th1 immunity is protective since it promotes humoral immunity, and phagocytic and cytotoxic T cell activity, whereas the Th2 response assists with the resolution of inflammation (Spellberg and Edwards, 2001) . Based on the ICS data, the immunization with 20 μg RBD fusion heterodimer/dose seems to induce a polarised Th1 immune response. Extracellular cytokine production was also measured by Luminex Multiplex in supernatants from splenocytes after 48 h of stimulation, where a balanced production of Th1 (TNF-α, IL-2) and Th2 (IL-5 but no IL-4 nor IL-6) cytokines was found in vaccinated mice. Notably, IFN-ɣ was not detected by Luminex, probably due to the early expression of this factor and its rapid degradation. Importantly, IL-10 was not detected in the supernatants, which indicates that the immunization with PHH-1V did not elicit an anti-inflammatory response after the re-stimulation of splenocytes with RBD peptide pools. The IgG2a/IgG1 ratio was measured for the assessment of the Th1/Th2 polarization after the prime-boost immunization. IgG1 is produced during any type of immune response, while IgG2a is mainly produced during a Th1-polarised immune response (Snapper and Paul, 1987) . Mice immunised with either 5 μg or 20 μg RBD fusion heterodimer/dose induced RBD-binding antibodies of both IgG2a and IgG1 subclasses, with an IgG2a/IgG1 ratio near 0.8, indicating a balanced Th1-Th2 response upon PHH-1V vaccination. Thus, all the data suggest that PHH-1V immunization with 20 μg RBD fusion heterodimer/dose elicits a robust CD4 + and CD8 + T cell response with an early expression of Th1 cytokines upon restimulation in vitro, and balanced Th1-Th2 cytokine production after 48 h post-stimulation. Regarding the preclinical efficacy of the PHH-1V vaccine candidate, it was tested at 2 different doses, 10 μg and 20 μg RBD fusion heterodimer/doses in K18-hACE2 mice. Upon the SARS-CoV-2 challenge, vaccinated animals were able to overcome the infection since neither clinical signs nor bodyweight loss was detected. Contrarily, all non-vaccinated and infected animals reached the end-point criteria at D5 or D6 post-challenge and had to be euthanised. Furthermore, this group of animals experienced a remarkable weight loss from D3 post-challenge onwards due to the SARS-CoV-2 infection. Therefore, our data show 100% efficacy in preventing mortality and body weight loss in infected K18-hACE2 mice upon PHH-1V vaccination. In addition, immunization with either the 10 μg or the 20 μg RBD fusion heterodimer/dose of PHH-1V reduced the viral load measured via qPCR in the lungs, nasal turbinate and brain in K18-hACE2 mice. The viral load excretion measured in oropharyngeal swabs was also reduced upon vaccination. Moreover, differences in the viral load after the SARS-CoV-2 challenge between vaccinated animals and infected non-vaccinated control animals were also found in other respiratory (trachea and pharynx) and systemic (spleen and heart) organs. Notably, when RT-qPCR positive samples were titrated to determine the infective viral load, most of the samples of vaccinated animals showed negative results, whereas, most of the samples of the infected control group resulted in significantly higher viral loads. Taken together, these results suggest less viral replication in vaccinated mice, which discards antibody-dependent enhancement (ADE) of the infection upon vaccination. Indeed, it is known that RBD poses a low potential for risk of ADE because antibodies against this domain block receptor binding (An et al., 2021) . Likewise, the histopathological evaluation of tissues from vaccinated mice showed no lesions in the brain and mild lesions in the lungs and nasal turbinate upon SARS-CoV-2 infection. Contrarily, infected control mice displayed moderate lesions in the lungs and brain, which is consistent with the high viral loads detected in this group. Overall, in this study, the PHH-1V vaccine has been shown to be safe and immunogenic in mice, inducing RBD-binding and neutralising antibodies. Mice immunised with 20 μg of recombinant protein RBD fusion heterodimer/dose showed neutralising activity against the alpha, beta, gamma and delta variants. Likewise, immunization with 20 μg of RBD fusion heterodimer/dose elicited robust activation of CD4 + and CD8 + T cells, producing an early Th1 response upon in vitro re-stimulation. Importantly, vaccination with either 10 μg or 20 μg RBD fusion heterodimer/dose prevented weight loss and clinical signs (including mortality) upon SARS-CoV-2 challenge in mice. Both tested doses reduced viral loads in several organs and prevented the infective viral load in the lungs and brain upon the experimental infection. In addition, immunization with 20 μg of RBD recombinant protein fusion dimer reduced the infective viral load in the upper respiratory tract (nasal turbinate). Most importantly, besides the efficacy and safety features of PHH-1V, this second-generation COVID-19 vaccine is easy to adapt to potential emergent SARS-CoV-2 variants, allowing for the inclusion of up to 2 different RBDs to generate cross-immunity against novel emergent variants. The PHH-1V vaccine candidate showed promising preclinical data and is currently being evaluated in a Phase I/IIa clinical trial (NCT05007509) (U.S. National Library of Medicine, 2021). The antigen was produced in a bioreactor based on a selected stable CHO-clone. A fed-batch strategy was used for high cell density cultivation and expression of the RBD fusion heterodimer. Upon harvest, the cell broth was clarified by depth filtration. The clarified supernatant was further purified via sequential chromatography. The purified antigen was then buffer exchanged by tangential flow filtration and filter sterilised. Purity and integrity were evaluated by SDS-PAGE with Bolt™ 4 to 12%, Bis-Tris gels (ThermoFisher, ref. NW04120BOX), stained with one-step blue protein gel stain (Biotium, ref. 21003) , and by SEC-HPLC with an xbridge protein BEH SEC (Waters, ref. 186009160) connected to a HP1100 system (Agilent Technologies). The affinity test of the RBD dimer with human ACE2 by surface plasmon resonance (SPR) was performed by ACROBiosystems. The Fc tagged ACE2 (AC2-H5257, ACROBiosystems) was immobilised in a Series S Sensor Chip CM5 (Cytiva) on a Biacore T200 (Cytiva) using the Human Antibody Capture Kit (Cytiva). The affinity measure was obtained using 8 different RBD heterodimer concentrations. The antigen structure simulations were performed with UCSF ChimeraX (Pettersen et al., 2021) . The purified RBD fusion heterodimer was formulated with an oil in water adjuvant, equivalent to MF59C.1. The PHH-1V vaccine was tested at different concentrations: 0.04 µg, 0.2 µg, 1 µg, 5 µg and 20 µg of RBD fusion heterodimer/dose for the safety and immunogenicity assays in BALB/c mice. For efficacy assessment in the K18-hACE2 mice animal model, the vaccine was tested at 10 µg and 20 µg of fusion heterodimer/dose. The placebo vaccines were prepared with Phosphate Buffered Saline (PBS). BALB/c mice (Envigo) and transgenic B6.Cg-Tg(K18-ACE2)2Prlmn/J (K-18-hACE2) (Jackson Laboratories) were used as animal models. All procedures that involved BALB/c mice were conducted in accordance with the European Union Guidelines for Animal Welfare (Directive 2010/63/EU) and approved by the Ethics Committee of HIPRA Scientific S.L.U. and the Department of Territori i Sostenibilitat of the Catalan Government (file: 11388). The experimental procedure that involved the use of K18-hACE2 mice were conducted in accordance with the European Union Guidelines for Animal Welfare (Directive 2010/63/EU) and was approved by the CMCiB Ethics Committee and the Department of Territori i Sostenibilitat of the Catalan Government (file: 11490). The animal study design followed the principles of the 3R's and animal welfare. Seventy-two (48F + 24M) 5-week-old BALB/c mice were allocated to 6 groups (n=12; 8F + 4M) and were used for safety and immunogenicity assays. Group A was vaccinated with PBS; group B was immunised with 0.04 μg recombinant protein RBD fusion heterodimer/dose; group C was immunised with 0.2 μg recombinant protein RBD fusion heterodimer/dose; group D was immunised with 1 μg recombinant protein RBD fusion heterodimer/dose; group E was immunised with 5 μg recombinant protein RBD fusion heterodimer/dose; and group F was immunised with 20 μg recombinant protein RBD fusion heterodimer/dose. These animals were monitored daily for clinical signs and bodyweight was recorded weekly until D35/D37; at that time, the animals were euthanised and tissues were collected. Animals were fed and watered ad libutum. For further safety, immunogenicity, and efficacy assays, 62 (31F + 31M) 4/5-week-old K18humanised ACE2 (hACE2) mice were allocated to 4 groups (n=18; 9F + 9 M except for the placebo group n=8; 4F + 4M). Specifically, group A was intramuscularly injected with PBS and noninfected, group B was injected with PBS and infected with SARS-CoV-2; group C was vaccinated with 10 μg/dose of recombinant protein RBD fusion heterodimer and infected with SARS-CoV-2; and group D was vaccinated with 20 μg/dose of recombinant protein RBD fusion heterodimer and infected with SARS-CoV-2. Animals from satellite subgroups were euthanised at D35 in order to assess the immunological response of the vaccinated group. Challenged animals were chronologically euthanised at D37, D39 and D42 (males)/D43 (females). Several tissue samples were collected for further analyses. Animal were fed and watered ad libutum. In order to comply with animal welfare regulations, all animals were injected with 0.1 mL/dose and they were distributed equally in both hind legs (2 x 50 μL). Animals from satellite subgroups were euthanized at D35 in order to assess the immunological response of the vaccinated group. Vaccines were injected intramuscularly following a two-dose prime-and-boost schedule: 1 st dose (prime) at D0 and 2 nd dose (boost) at D21. The SARS-CoV-2 challenge was performed through intranasal inoculation on a subset of animals at D35 with 25 µL in each nostril (10 3 TCID50/mice in 50 μL/mice). The intranasal experimental infection was performed under sedation with isoflurane 4-5%. BALB/c vaccination and sampling were performed at HIPRA (Girona, Spain). K18-hACE2 mice vaccination, SARS-CoV-2 challenge, and sampling were performed in the ABSL3 unit of the Comparative Medicine and Bioimage Centre of Catalonia of the Germans Trias i Pujol Research Institute (Badalona, Spain). The protocol followed is depicted in Figure S5 . Serum binding antibodies against SARS-CoV-2 RBD were determined by ELISA (HIPRA). MaxiSorp plates (Nunc, Roskilde, Denmark) were coated with 100 ng/well RBD protein (Sino Biologicals, Beijing, China) and blocked with 5% non-fat dry milk (Sigma-Aldrich, St. Louis, MO, USA) in PBS. Wells were incubated with serial dilutions of the serum samples and the bound total IgG specific antibodies were detected by Peroxidase-conjugated Goat Anti-Mouse IgG (Sigma-Aldrich). Finally, wells were incubated with K-Blue Advanced Substrate (Nirco, Madrid, Spain) and the absorbance at 450 nm was measured using a microplate reader (Synergy HTX). The mean value of the absorbance was calculated for each dilution of the serum sample run in duplicate. Isotypes IgG1 and IgG2a were detected using peroxidase affinipure goat anti-mouse IgG, Fcγ subclass 1 specific and peroxidase affinipure Goat anti-mouse IgG, Fcγ subclass 2a specific (Jackson ImmunoResearch, Cambridgeshire, UK), respectively, as a secondary antibody. The end-point titre of RBD-specific total IgG binding antibodies was established as the reciprocal of the last serum dilution that gave 3 times the mean optical density of the negative control of the technique (wells without serum added). Neutralising antibodies in serum against SARS-CoV-2 Wuhan (original sequence), and the alpha, beta, gamma and delta variants were determined by a pseudoviruses-based neutralization assay (PBNA) at IRSICaixa (Barcelona, Spain), using an HIV reporter pseudovirus that expresses the S protein of SARS-CoV-2 and luciferase. Pseudovirus were generated as described in Pradenas et al., 2021 . For the neutralization assay, 200 TCID50 of pseudovirus supernatant was preincubated with serial dilutions of the heat-inactivated serum samples for 1 h at 37 °C and then added onto ACE2 overexpressing HEK293T cells. After 48 h, cells were lysed with britelite plus luciferase reagent (PerkinElmer, Waltham, MA, USA). Luminescence was measured for 0·2 s with an ensight multimode plate reader (PerkinElmer). The neutralization capacity of the serum samples was calculated by comparing the experimental RLU calculated from infected cells treated with each serum to the max RLUs (maximal infectivity calculated from untreated infected cells) and min RLUs (minimal infectivity calculated from uninfected cells), and expressed as the neutralisation percentage: Neutralisation (%) = (RLUmax-RLUexperimental)/(RLUmax-RLUmin) * 100 (Trinité et al., 2021) . IC 50 were calculated by plotting and fitting neutralization values and the lo fog plasma dilution to a 4-parameters equation in Prism 9.0.2 (GraphPad Software, USA). The ICS was performed by the Infection Biology group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (DCEXS-UPF, Barcelona, Spain). Spleens from female mice were mechanically disrupted onto a 40 µM cell strainer and incubated in 5 mL of 0.15 M ammonium chloride buffer for 5 min at room temperature (RT) for red blood cell lysis. Cells were then washed in RPMI (Gibco, Tavarnuzze, Italy) supplemented with 10% FBS, 1% penicillin/streptomycin, 0.05 mM-Mercaptoethanol and 1 mM sodium pyruvate (cRPMI). Two million splenocytes per well (96-well plate) were stimulated in vitro under three conditions: (i) a 1:1 mix of the peptide libraries (PepMix™) from the B.1.1.7 (α variant) and B.1.351 (β variant) lineages covering the entire RBD of the SARS-CoV-2 S protein; (ii) cRPMI (negative control); and (iii) PMA + Ionomycin (positive control) for 5h at 37C 5% CO2 in cRPMI in the presence of Brefeldin A (Sigma-Aldrich) for the last 3h before antibody staining. The final concentrations used were 1 µg/mL of each peptide of the RBD peptide pool, 15 ng/mL of PMA (Sigma-Aldrich) and 250 ng/mL of ionomycin (Sigma-Aldrich). For flow cytometric analysis, equal numbers of cells were stained with fixable viability stain 780 (BD Biosciences, New Jersey, NJ, USA) in PBS for 15 min at RT followed by staining with antibodies against CD3, CD4, CD8 and CD44 for 20 min on ice in FACS buffer (PBS 5% FCS, 0.5% BSA, 0.07% NaN3). Cells were then fixed for 20 min on ice with 2% Formaldehyde and stained with antibodies against intracellular proteins (IFNγ, TNFα, IL-2 and IL-4) for 20 min on ice in perm/wash buffer (PBS 1% FCS, NaN3 0.1%, Saponin 0.1%). All antibodies were purchased from either BD Biosciences, ThermoFisher or BioLegend (See Table S1 for more details). Samples were processed on an Aurora (Cytek, Fremont, CA, USA) analyser. FACS data were analysed using flowjo 10 software (Tree Star Inc., Ashland, OR, USA). The stain index was calculated by subtracting the mean fluorescence intensity (MFI) of the unstained or fluorescence minus one (FMO) control from the MFI of the stained samples and dividing it by two times the standard deviation of the unstained population. Background cytokine expression in the no-peptide (cRPMI) condition was subtracted from that measured in the RBD peptide pool for each mouse. The cytokine assay was performed by the Infection Biology group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (DCEXS-UPF, Barcelona, Spain). Splenocytes from female mice were seeded at 1.1 × 10 6 cells/well in 24-well plates and stimulated with a 1:1 mix of the RBD overlapping peptides from B.1.1.7 (alpha variant) and B.1.1351 (beta variant) lineages (1 μg/mL each). cRPMI media was used as a negative control and PMA (15 ng/mL) + Ionomycin (250 ng/mL) as a positive control. The supernatants were harvested after 48 h incubation at 37 °C and a panel that quantifies the cytokines IL-2, IL-4, IL-5, IL-6, IL-10, IFN-γ and TNF-α (Luminiex Multiplex, Invitrogen, Waltham, MA, USA) was run according to the manufacturer's instructions. These measurements were performed at Servei Bioquímica Veterinària, Facultat de Veterinària, Universitat Autònoma de Barcelona (UAB, Barcelona, Spain). ELISpot assays were performed with mouse IFN-γ and IL-4 ELISpot PLUS kits according to the manufacturer's instructions (3321-4HPT-10 and 3311-4HPW-10, Mabtech, Herndon, VA, USA). A total of 2,5 × 10 5 or 4 x 10 5 splenocytes from female mice were seeded per well for the IFN-γ and IL-4 tests respectively and ex vivo stimulated either with the 1:1 mix of the RBD overlapping peptides from the B.1.1.7 (alpha variant) and B.1.351 (beta variant) lineages (1 μg/mL each), or with complete cRPMI (negative control) or with Concanavalin A (5 μg/ml (Sigma-Aldrich)) (positive control). Each condition was run in duplicates. After an incubation period of 18-20 h (for IFN-γ) or 48 h (for IL-4), the plates were manipulated according to the manufacturer's instructions. Spots were counted under a dissection microscope. Frequencies of IFN-γ or IL-4secreting cells were expressed as the number of responding cells per million splenocytes. The number of spots in unstimulated cultures (negative control) was subtracted from the spot count in RBD-stimulated cultures. Total viral load in respiratory tissue samples was determined by RT-qPCR (CReSA, IRTA-UAB, Barcelona, Spain), according to the method described by Brustolin et al. (2021) . Virus titres were determined using a standard TCID50 assay in Vero E6 cells at CReSA (IRTA-UAB), according to the method described by Brustolin et al., 2021 . TCID50/ml results were transformed to PFU/ml units by multiplying TCID50/ml titre by 0.7 according to the ATCC (ATCC Technical Support recommendations, 2021). To express viral titres in PFU/g, lungs and nasal turbinate samples were determined at necropsy on days 2, 4, 7 or 8 post-infection (and at the time the euthanasia was required). Histopathological analyses were performed at CReSA (IRTA-UAB). Upper (nasal turbinate) and lower (lung) respiratory tract and brain were fixed in 10% buffered formalin and routinary processed for histopathology. Haematoxylin-and eosin-stained slides were examined under optical microscope. Multifocal broncho-interstitial pneumonia, multifocal lymphoplasmacytic rhinitis and non-suppurative meningoencephalitis were evaluated from: lung nasal turbinate and brain lesions, respectively, according to the following score: 0 (no lesion), 1 (mild lesion), 2 (moderate lesion) and 3 (severe lesion) (Brustolin et al., 2021; Vidal et al., 2021) . All statistical analyses were performed using R (version 4.0.5), SPSS (version 22), and/or GraphPad Prism (version 9). In all plots, individual data points were depicted for each mouse along with the sample mean and Standard Deviation (SD) as a representation of their distribution. Significant comparisons at 5% significance level and trends were indicated in each plot (p<0.05: *; p<0.01: **; 0.05